Results Suggest that DNA Tagging can be Applied to other Premier Fibers for Field-to-Finished-Garment Authentication

STONY BROOK, N.Y., November 05, 2018 – Results of a new study published in the September/October 2018 issue of the AATCC Review confirmed that DNA molecular tagging is an effective tool to authenticate denim and maintains its integrity even after exposed to the rigors of bleaching and abrasion.

The study was conducted by: Applied DNA Sciences, Inc. (“Applied DNA,” “the Company,” NASDAQ: APDN), and the Fashion Institute of Technology (FIT).  It was published in the AATCC Review, a highly regarded publication of the American Association of Textile Chemists and Colors.

At the FIT labs in New York, denim swatches were treated with unique DNA molecular tags produced by Applied DNA, then subjected to stone and bleach washings. The samples were then analyzed at Applied DNA’s laboratories in Stony Brook, where it was proven that the DNA tags remained intact and suitable for high quality forensic scale analysis. Based on the observed stability, DNA tags of this kind may soon be ready for testing at a full manufacturing facility to verify the authenticity of the finished denim garment.

“This technology will enable brands and manufacturers to track their fibers from the farm through to the finished product, allowing for a more transparent supply chain. Traceability can also help verify certain sustainability claims about commodities and products, helping ensure good practices and respect for people and the environment in supply chains,” Sean Cormier, FIT Assistant Professor, Textile Development and Manufacturing.

“A denim fabric was chosen because it is a unique product, distinguished by its washed styles and distressed look,” said Dr. James A. Hayward, president and CEO of Applied DNA Sciences. “Denim jeans are typically exposed to a stone and bleach wash, which is the harshest type of treatment made to any apparel product. If we could identify our DNA markers after this type of wash, we believe any cotton product could be identified at any stage in the supply chain.”

Applied DNA has developed a technology to produce small DNA fragments or identifiers on an industrial scale. Purified enzymes are used to manufacture DNA fragments, each one containing enough information to be used as a DNA-bead or “molecular bar code,” much like an ordinary ink bar code on a label.  DNA tags are applied during the cotton ginning phase, enabling the fiber to be tracked and authenticated throughout the entire supply chain.

There has been a lack of commercially available test methods to determine where denim fibers were grown. This is a concern to manufacturers, as global counterfeiting continues to escalate – rising from USD $1.2 trillion in 2017 to an anticipated USD $1.82 trillion by 2020 (Global Brand Counterfeiting Report 2018). The denim authentication problem is significant since most American cotton, including Upland cotton used to produce denim, is shipped overseas and combined with other cotton where it can lose its identity.

“The denim study has opened the door to a world of possibilities,” Hayward added. “These results suggest that it is now possible to assign several unique DNA molecular tags to any cotton product, regardless of finish. Future projects will tag cotton intended for denim use, as well as other premium fibers such as wool, cashmere, as well as man-made fibers like viscose, nylon, recycled polyester and also bio-based fibers and recycled materials,” he explained.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Contact Us
investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Angie Mathews, 781-639-4924, angie@cgprpublicrelations.com
program contacts: MeiLin Wan, 631-240-8849, meilin.wan@adnas.com
web: www.adnas.com
twitter: @APDN

Inspired by Applied DNA Sciences’ molecular-tagging technology, a global textiles manufacturer is climbing into bed with the “circular economy.”

Actually, India-based GHCL Ltd. has already bedded the so-called circular economy (referencing a regenerative system in which waste and emissions are minimized by narrowing energy and material loops, mostly through recycling and manufacturing upgrades). The manufacturer is knee-deep in recycled materials, including entire linen lines formulated from recycled polyethylene terephthalate (you may know it better as PET, or the stuff your Pepsi bottle is made from).

GHCL, a Global Home Textiles Player, Creates “CIRKULARITY”, a Brand Platform, Inspired By “REKOOP” Sustainable, Traceable, Recycled Polyester Bedding

“REKOOP” is the first Bedding solution to use Applied DNA’s CertainT Platform and Reliance Industries’ Recron GreenGold fiber for source verification and traceability of recycled polyester across the supply chain; Arrives in US Q1 2019

STONY BROOK, N.Y., October 29, 2018 – Global manufacturer of home textiles GHCL, Limited (listed on NSE and BSE) launched CIRKULARITY™, a new brand of eight lines of bedding supporting the circular economy in September, at the New York home fashions market week. These lines center on “reduce, reuse and recycle”. REKOOP®, the inspiration behind CIRKULARITY, is a brand of bedding products made from recycled plastic (rPET) and is the first bedding product to use Applied DNA Sciences’ (“Applied DNA,” “the Company,” NASDAQ: APDN) CertainT^® platform. REKOOP bedding products will be available for sale in the US beginning first quarter 2019.

REKOOP uses Applied DNA’s CertainT platform to trace and authenticate the post-consumer recycled polyester plastic in its bed sheets, pillowcases, and shams throughout the entire supply chain. This technology provides forensic proof that goes beyond a paper document. It guarantees brand authenticity, a growing concern for manufacturers as counterfeiting continues to escalate – rising from USD $1.2 trillion in 2017 to an anticipated USD $1.82 trillion by 2020.

“We are proud to introduce REKOOP, the first fully source-verified recycled PET bedding product line,” said Manu Kapur, president and CEO of GHCL Home Textiles. “Applied DNA’s CertainT platform provides customers and brands with the highest level of trust in terms of the authenticity of their products.”

REKOOP uses polyester made from recycling post- consumer PET bottles. With 36 plastic bottles used for each sheet or the equivalent of one ton of plastic (36,000 bottles) in 1000 sheets, helps reduce these PET bottles landing into the landfills, crude oil consumption and carbon emissions.

“REKOOP bedding highlights the interest brands have in providing consumers a verifiable guarantee,” said Dr. James A. Hayward, president and CEO of Applied DNA. “CertainT does what no other system can do; we can provide a unique, customized tag for every single fiber and verify them through a defined and secure supply chain through systematic sampling, testing and tracking. Momentum with retailers and manufacturers across a variety of textiles is growing and we are pleased to see the CertainT platform and trademark now making its way onto retail shelves next year,” he added.

Reliance Industries Ltd. (RIL), India’s largest private company, provides its ecofriendly Recon^® Green Gold, a high-quality fiber designed for REKOOP. As part of the integrated supply chain for REKOOP, Reliance is also partnering with Applied DNA Sciences in the use of the molecular-based solution for recycled PET to produce certified fiber for home textiles, apparel, footwear and other applications.

“Reliance is pleased to engage in a collaboration with two premier and forward-focused entities. “Textile manufacturing must change from linear to circular paradigms to ensure transparency, authenticity and sustainability. We will work closely with Applied DNA Sciences and GHCL to forge new paths to bring required changes to drive circular concept in the industry.” said Hemant Sharma, Head – Polyester Sector, Reliance Industries Ltd.

Operating its home textiles facility in Vapi, Gujarat, India, GHCL incorporated the CertainT verified rPET fiber into its production process, from spinning to weaving to finished processed fabric. One of the leading manufacturers in home textiles in India, the plant boasts an annual production capacity of 36 million meters of finished fabric per annum.

For more information, please visit www.rekoop.pet.

About GHCL
GHCL is a well-diversified group with footprints in Chemicals, Textiles and Consumer Products segment. GHCL’s Textiles division is a vertically integrated manufacturing facility with spinning, wider-width weaving, continuous fabric processing, and cut & sew facilities for manufacturing premium quality bed linen. GHCL is one of India’s leading manufacturers of Home Textiles, with in-house spinning unit having capability to manufacture multiple varieties of 100% cotton and blended yarns at various facilities.

GHCL is known as perennial innovators in bed linen category with some of recent innovations in the category of ‘sheets’ which include the PERFECT FIT, EASYSHEET, microTWILL, CELLIANT, EXL Wrinkle Free Sheets, VERSATILE–Reversible Sheets, Soft Wash Percale and Sustainable Fibre dyed sheets.

GHCL’s Home Textiles products are predominantly exported worldwide to countries like United Kingdom, United States of America, Australia, Canada, Germany and other European Union countries as well.

About Reliance Industries
RIL is India’s largest private sector company, with a consolidated turnover of INR 430,731 crore ($ 66.1 billion), cash profit of INR 56,034 crore ($ 8.6 billion), and net profit of INR 36,075 crore ($ 5.5 billion) for the year ended March 31, 2018.

RIL is the first private sector company from India to feature in Fortune’s Global 500 list of ‘World’s Largest Corporations’ – currently ranking 148th in terms of revenues and 99th in terms of profits, the most profitable Indian company on the list. The company stands 83rd in the ‘Forbes Global 2000’ rankings for 2018 – the top-most among Indian companies. It ranks amongst LinkedIn’s ‘Top Companies Where India Wants to Work Now’ (2018). RIL’s activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and 4G digital services.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777,shurry@lhai.com
media contact: Angie Mathews, 781-639-4924, angie@cgprpublicrelations.com
program contacts: MeiLin Wan, 631-240-8849, meilin.wan@adnas.com
Deepika Abrol, 0120 3358180, deepikaabrol@ghcl.co.in

Reflects continuing demand for traceable cotton and synthetic textiles, new food-based agriculture applications and growing LineaRx business

STONY BROOK N.Y., October, 24, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, has entered its FY2019 with strong momentum in the first month in textiles, food-based agriculture and through the LineaRx subsidiary. Textiles business expansion includes a shipment of taggant for the upland Delta cotton variety in the current 2018-2019 ginning season, two new pilots for the Company’s CertainT^® system in synthetic textiles (following one additional customer pilot completed in September) and one new feasibility study for the tagging of a food-based agricultural commodity. LineaRx, the Company’s wholly-owned subsidiary focused on next-generation biotherapeutics, received a new order for PCR-produced DNA for biotherapeutic application(s).

“Our structure for managing people, processes and technologies supporting global cotton supply chains, from the U.S. and Australian cotton gins, to local customer sales and support in India and Europe, through to our testing labs in Stony Brook and Ahmedabad, India and our partnerships with IT platform companies, has been a necessary investment for our unique selling proposition in end-to-end supply chain traceability. This sets a foundation from which our other supply chain pilots can be initiated and completed more quickly,” stated Dr. James Hayward, president and CEO of Applied DNA.

Continued Dr. Hayward: “Our LineaRx opportunity looks strong, with steady inquiries incoming for DNA biotherapeutic products as the benefits of linear, PCR-produced DNA is highlighted in the media.”

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Applied DNA’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, 917.733.5573, sanjay.hurry@adnas.com
Web: www.adnas.com
Twitter: @APDN

Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies.

By GREGORY ZELLER //OCTOBER 16, 2018

Marking a big step in the war against cancer, a Stony Brook-based startup has initiated pre-clinical development of a non-viral, plasmid-free chimeric antigen receptor modified T-cell manufacturing platform.

In English: A novel platform designed to develop and manufacture new pharmaceutical treatments, including treatments for different forms of cancer.

Goal Is the Development of Faster, More Affordable Therapies

Streamlined manufacturing processes could yield reduced cost and lead times, lessening patient morbidity and mortality through shorter “vein-to-vein” times. [Applied DNA Sciences]

By MaryAnn Labant

A rapidly emerging immunotherapy approach, adoptive cell transfer (ACT), collects and uses a patient’s own immune cells to treat their cancer. One methodology, Chimeric Antigen Receptor T-Cell (CAR T-cell) therapy, has advanced the furthest in clinical development. Various B-cell malignancies can be addressed with CAR-modified T cells by targeting CD19, a protein that is expressed on the vast majority of B-cell cancers.

Novel DNA Manufacturing Platform Pioneering a New Generation of Faster, More Affordable CAR T Therapeutics. Offering Available to CRO/CMO Customers.

STONY BROOK, N.Y., October, 16, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has initiated pre-clinical development of a non-viral, plasmid-free (NVPF) chimeric antigen receptor (CAR) modified T cell (CAR T) manufacturing platform which will be made available to CAR T developers worldwide. Concurrently, LineaRx announced the signing of an exclusive North American licensing agreement and research services agreement with iCell Gene Therapeutics, Inc. (iCell) under which iCell licensed to LineaRx an anti-CD19 CAR T therapy for non-viral delivery. LineaRx will utilize its NVPF platform, along with the in-licensed anti-CD19 CAR T therapy, to develop, manufacture and commercialize LinCART19, a non-viral, plasmid free anti-CD19 CAR T drug candidate.

“Since their initial FDA approval in 2017, CAR T therapies have shown unrivaled efficacy against several forms of cancer, but they remain extremely complex to manufacture and are often cost prohibitive,” stated Dr. James Hayward, president and CEO of Applied DNA. “With our expertise in the large-scale PCR-based production and modification of DNA constructs, we believe we are in a unique position to offer a disruptive, inexpensive and safer alternative to established CAR T manufacturing platforms that rely on viral vectors and plasmids. We are excited to have begun pre-clinical development of our NVPF CAR T manufacturing platform to enable a new generation of cell therapies, including our own LinCART19 CAR T therapy, and offering CAR T developers worldwide access to our manufacturing platform upon completion of development.”

Said Dr. Stephen Hughes, Director of DNA Programs at Applied DNA: “CAR T therapies are changing the treatment of cancer, but they must be affordable and accessible to all patients. We believe the approach of the LineaRx team will alter the manufacturing of these life-changing therapies, increasing the speed and safety of production, while lowering the costs.”

LineaRx believes its novel NVPF construction of CAR Ts provides a manufacturing format that would be attractive to many developers of these therapies. Despite costly and inefficient manufacturing platforms, the CAR T market is currently experiencing rapid growth and investment, with over $20 billion in recent M & A activity¹, and is expected to yield a CAGR of 32.5% at least through 2028².The NVPF LineaRx CAR T manufacturing platform under development leverages Applied DNA’s expertise in large-scale PCR-based production and chemical modification of DNA to produce expression vectors for CAR T therapy, without the use of viral vectors or plasmids. LineaRx believes that a NVPF CAR T manufacturing platform confers numerous potential advantages over existing viral/plasmid-based CAR T platforms, including:

• Streamlined manufacturing processes will yield reduced cost and lead times, lessening patient morbidity and mortality through shorter “vein-to-vein” times. As seen in the registrational trials for Kymriah^® (Novartis International AG) and Yescarta^® (Kite Pharma Inc.), the two currently US FDA approved CAR T therapies, up to 31% of intended patients ultimately did not receive treatment primarily due to patient complications during disease progression which evolved during the long manufacturing time required or from manufacturing failures,³
• Reduction in the risk of permanent genetic integration/recombination into target cells, reducing the risk of insertional mutagenesis,
• The potential mitigation of some current CAR T therapy side effects such as cytokine release syndrome (CRS) and on-target off-tumor toxicity,
• The eventual ability to target neoantigens (quickly enough to impact the patient), or the patient-specific protein mutations that accrue in an individual patient’s cancer, and other disease epitiopes beyond cancer, that will allow a patient’s immune system to be the instrument of diverse therapies, and,
• The eventual ability to develop CAR T therapies at the point-of-care, obviating complex and burdensome distributed supply chains, and consequently, speeding therapy.

LinCART19 CAR T therapy, which targets the CD19 B cell surface protein expressed on nearly all B-cell malignancies, is the focus of a research agreement between LineaRx and iCell Gene Therapeutics. Development of LinCART19 will benefit from iCell Gene Therapeutics experience in bringing the virally transfected CD19 targeted CAR-T successful into human clinical study as well as their technological leadership in engineering novel, first in class adoptive cell therapies.

After recently announcing a cancer vaccine will utilize its technology, LineaRx is leveraging its NVPF manufacturing platform for its LinCART19 CAR T therapy. This demonstrates the potential breadth of the NVPF platform to produce various biotherapeutics, including gene and cellular therapies as well as vaccines, subject to FDA approval.

Dr. Hayward continued, “We believe our NVPF approach to generate important biotherapeutics without using viruses and plasmids using portable devices can redefine “bench to bedside” therapy. Our Linear DNA PCR devices can be located on site, so the supply chain will never leave the building. We anticipate partnering with other developers to generate fundamentally new drugs from CAR Ts, including using custom epitopes and neoantigens to help usher personalized cancer therapy from a dream to reality.”

¹BioInformant
²Coherent Market Insights
³ Allogene Therapeutics, Inc. Form S-1, filed September 14, 2018

CAR T Therapies
CAR T therapies are a revolutionary DNA based approach to destroy cancer cells by harnessing the power of a patient’s own immune system. CD19 is a protein that is expressed on the vast majority of B cell cancers. By targeting CD19 expressing B cells with CAR modified T cells, various B cell malignancies can be addressed. Since 2017, the FDA has approved two CAR T-based therapies targeting the CD19 epitope, opening a new frontier in the fight against cancer.

About iCell Gene Therapeutics, Inc.
iCell Gene Therapeutics is developing proprietary technologies and a pipeline of Chimeric Antigen Receptor (CAR) engineered cell therapies designed to be first in class, cost effective and life saving. Our development operations are focused on creative and efficient paths to bring novel, cost effective therapies to patients.  First in human clinical trials are ongoing in US & China, supported by our US research & development organization and a state-of-the-art GMP facility in Zhongshan to manufacture precision-based therapeutics.

About LineaRx
LineaRx seeks to commercialize the biotherapeutic value of Applied DNA’s deep expertise and experience in the design, manufacture and chemical modification of DNA by large scale polymerase chain reaction (“PCR”). Linear DNA is a form of DNA distinct from the circular form of DNA most commonly produced in plasmids and grown in bacteria.  Plasmids are extrachromosomal DNA found in bacteria and are associated with the genes for antibiotic resistance which are often exchanged between bacteria and consequentially, are seen by many to embody a serious threat to global health. In addition, many nucleic acid-based therapies also rely on viral vectors for efficient transfection and expression of plasmid DNA. These viral vectors carry additional nontrivial risks and are extremely time consuming and expensive to manufacture.In all forms of gene therapy, DNA exerts its influence from within the nucleus.  Recombinant events for circular DNA are permanent and alter the genomes of the affected cells and their progeny. The fundamental challenge of all gene and cellular therapies is safety.  Recent studies have elaborated “unintended consequences” when plasmid and viral vectors are combined that may pose future risks for treated patients.When linear DNA enters the nucleus, it does not need to be incorporated into the genome to be temporarily expressed as the intended protein product. LineaRx posits that for the effectiveness of genetic vaccines or genetic immune therapies, transient expression may be sufficient.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and therapeutics.

We make life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. The proprietary DNA-based “CertainT^®” platform can be used to identify, tag, test, and track products, to help assure authenticity, origin, traceability, sustainability and quality of products.

SigNature^® DNA describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions such as SigNature^® T and fiberTyping^®, targeted toward textiles and apparel, BackTrac™ and DNAnet^®, for anti-theft and loss prevention, and digitalDNA^®, providing powerful track-and-trace. All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the large-scale production of specific DNA sequences using the polymerase chain reaction.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company’s common stock is listed on NASDAQ under the symbol APDN, and its warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to our history of losses, limited financial resources, limited market acceptance and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 28, 2017 and our subsequent quarterly reports on Form 10-Q filed on February 8, 2018, May 3, 2018 and August 13, 2018, which are available at www.sec.gov. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
media contact: Cheryl Schneider, DGI Comm, 212-825-3210, cschneider@dgicomm.com
program contact: Brian Viscount, Executive Director Product Management, 631-240-8800, brian.viscount@adnas.com
web: www.adnas.com, www.linearxdna.com
twitter: @APDN, @LineaRxDNA

By Judy Murrah, Applied DNA Sciences

Counterfeit drug products are a major problem for the pharmaceutical industry. This article discusses how DNA molecular taggants can help combat drug counterfeiting and improve the safety of the pharmaceutical supply chain.

Applied DNA Sciences, a leader in large-scale PCR-based DNA manufacturing, has appointed Wayne Buchen as Vice President of Strategic Sales to lead the company’s global textile strategic sales efforts. With over 20 years of sales, sourcing and operations experience with established international brands, Mr Buchen will drive the development and execution of sales strategies to expand Applied DNA’s presence across global textiles markets.